Atalanta Therapeutics Secures USD 97 Million Series B for Groundbreaking Neurological Treatments
Deal News | Jan 28, 2025 | EQT
Atalanta Therapeutics, a biotechnology firm based in Boston, is advancing the development of treatments for neurological diseases using RNA interference (RNAi) technology. The company has secured a USD 97 million Series B funding, led by EQT Life Sciences. The Series B financing will support Phase 1 clinical trials of RNAi therapies targeting KCNT1-related epilepsy and Huntington's disease. EQT Life Sciences invested through the LSP Dementia Fund, co-leading alongside Sanofi Ventures, with significant contributions from RiverVest Venture Partners, abrdn, Inc., Mirae Asset Financial Group, and F-Prime Capital. Atalanta's proprietary RNAi platform, di-siRNA, marks a breakthrough in enabling RNAi as a therapeutic option for the brain and spinal cord, potentially silencing harmful genes. With this funding, Atalanta aims to initiate Phase 1 trials next year, focusing on advanced treatments for severe neurological conditions lacking disease-modifying therapies. The announcement reflects the firm's strategic collaborations and investment synergy within a robust financial ecosystem.
Sectors
- Biotechnology
- Healthcare
- Private Equity
Geography
- United States – The primary focus is on Atalanta Therapeutics, a biotech company headquartered in Boston, Massachusetts.
- Europe – EQT Life Sciences, part of the EQT platform, has European origins and contributes to the article's international investment perspective.
Industry
- Biotechnology – The article focuses on Atalanta Therapeutics, a biotech company developing RNAi therapies for neurological disorders.
- Healthcare – The development and funding of neurological treatments places the article within the healthcare sector.
- Private Equity – EQT Life Sciences, a private equity firm, leads the Series B funding, underlining the involvement of private equity in strategic biotech investments.
Financials
- USD 97 million – Total amount raised in the Series B financing round led by EQT Life Sciences.
- USD 240 million – Total capital raised by Atalanta Therapeutics to date from all financings and partnerships.
- USD 297 million – Total size of the LSP Dementia Fund from which EQT Life Sciences invests.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Atalanta Therapeutics | Target company | Company | A Boston-based biotech firm pioneering RNAi technologies for neurological disease treatment. |
| EQT Life Sciences | Lead investor | Company | A division of EQT, focused on investments in life sciences and healthcare, leading the Series B round. |
| Sanofi Ventures | Co-lead investor | Company | Corporate venture arm of Sanofi, involved in co-leading the funding round. |
| RiverVest Venture Partners | Investor | Company | A venture capital firm participating in the Series B financing. |
| abrdn, Inc. | Investor | Company | An investment company contributing to the funding round. |
| Mirae Asset Financial Group | Investor | Company | Global financial services group, participating in the investment round. |
| F-Prime Capital | Investor | Company | A venture capital firm participating as an existing investor in the funding round. |